About Michael T. Ledet, M.D.

Michael T. Ledet, MD, is CEO of Sleep & CardioVascular Health in Daphne, Alabama and is board certified in Family Medicine, Sleep Medicine, and Lipidology. He also serves as Medical Director at Southeast Regional Center for Sleep/Wake Disorders since its inception in the early 1990s. His focus of healthcare is on sleep and cholesterol disorders to prevent and manage cardiovascular disease, which includes caring for risk factors such as insulin resistance. He enjoys participating as primary investigator for research trials at Coastal Clinical Research, now AMR-Mobile.

He lives in Montrose with his wife, Toni, and he has three children who also reside in Baldwin County.


Full Name: Michael Thomas Ledet, M.D.
Professional Address: CEO, Sleep & Cardiovascular Health
7101 Hwy 90, Suite 102
Daphne, AL 36526


1976 – 1980 B.S. in Mathematics Honors Scholar
University of Alabama, Tuscaloosa, AL

1980 – 1984 M.D.; University of South Alabama College of Medicine
Medical School Training, Mobile, AL

1984 – 1987 Tallahassee Memorial Regional Medical Center
Family Medicine Residency, Tallahassee, FL


2022- Present
CEO, Sleep & CardioVascular Health
Daphne, AL

1987 – Present
Medical Director, Southeast Regional Center for Sleep/Wake Disorders
Springhill Medical Center, Mobile, AL

1987 – Present
Assistant Clinical Professor, Family Practice Department
University of South Alabama College of Medicine, Mobile, AL

2014 – Present
Coastal Clinical Research, Investigator

2008 – 2022
Director, Preventive Care & Sleep Medicine
Springhill Physician Practice, Mobile, AL

2002 – 2008
Director, Preventive Care & Sleep Medicine
Internal Medicine Center, Mobile, AL

1999 – 2007
Investigator, Sunbelt Research Group

1987 – 2002
Family Practice Associates of Mobile
Mobile, AL

portrait of Dr Michael Ledet


  • 1987 – Present, Alabama Medical Licensure Commission (12669)
  • 1998 – 2013, 2019 Member, America’s Best Doctors
  • 2020, Leading Physicians of the World


  • Current Family Medicine
  • Current Sleep Medicine
  • Current Lipidology


Ledet, M., Sleeping Away Diabetic Complications, Practical Diabetology; Sept/Oct 2010



2014 – Present Coastal Clinical Research, Inc.



Galt Pharmaceuticals


1999 Sub-Investigator; Amgen, Inc.; Long-Term Safety of Daily Subcutaneous Injections of Anakinra in Patients with Rheumatoid Arthritis

2000 Investigator; Glaxo Wellcome; Primary Care Study to Estimate the Prevalence of Sexual Dysfunction Reported by Patients Currently Taking New Generation Antidepressant Medication for a Diagnosis of Depression

2000 Sub-Investigator; Amgen Inc.; Placebo Controlled Trial to Study the Ability of IL-1ra to Retard Joint Destruction, and Evaluate the Long Term Safety of IL-1ra, in Subjects with Rheumatoid Arthritis

2000 Investigator; Bristol-Myers Squibb; Pravastatin Inflammation / CRP Evaluation Trial

2000 Investigator; Glaxo Wellcome; Patient Treatment for and Satisfaction with Migraine Therapy: Imitrex Tablets versus Current Therapy

2000 Investigator; Bristol-Myers Squibb; Omapatrilat Cardiovascular Treatment versus Enalapril (OCTAVE)

2001 Investigator; Glaxo Wellcome; Surviellance Study of Asthma Event Outcomes in Subjects Receiving Either Usual Pharmacotherapy of Asthma or Usual Pharmacotherapy Plus Salmeterol Twice Daily

2001 Investigator; Ortho-McNeil; Safety and Efficacy Study of Levofloxacin 750mg Once Daily for Five Days vs. Levofloxacin 500mg Once Daily for Ten Days in the Treatment of Mild to Severe Community-Acquired Pneumonia in Adults

2001 Investigator; Ortho-McNeil; Open Label Study to Evaluate the Safety and Efficacy of Levofloxacin 750mg Once Daily for Five Days in the Treatment of Mild to Severe Community-Acquired Pneumonia in Adults

2001 Investigator; Ortho-McNeil; A Randomized, Multicenter, Blinded Study of the Efficacy and Safety of High-Dose (750MG), Short-Course (3-5 Days) Levofloxacin Therapy in Uncomplicated and Complicated Acute Bacterial Exacerbation of Chronic Bronchitis

2001 Investigator; Aventis Pharmaceuticals; Telithromycin Respiratory Effectiveness Assessment Trial (TREAT)

2002 Investigator; GlaxoSmithKline; Open Label Study Assessing Paxil CR in Subjects with Major Depressive Disorder who Discontinued Treatment with SSRS or a SSNRI due to Intolerability

2003 Investigator; Neurocrine Biosciences, Inc.; Phase III Study to Assess the Long-Term Safety and Efficacy of Two Dose Levels of NBI-34060 in Adult Patients with Primary Insomnia

2004 Investigator; Sepracor, Inc.; The Efficacy of Eszopiclone 3mg Compared to Placebo in the Treatment of Insomnia Secondary to Perimenopause or Menopause

2004 Investigator; NeurogesX, Inc.; Randomized, Open-Label Study of the Tolerability of Three Local Anesthetic Formulations in Conjunction with NGX-4010 for the Treatment of Neuropathic Pain

2004 Investigator; Pfizer, Inc.; Randomized, Double-Blind, Placebo-Controlled, Multicenter Actual Use Study of the Safety and Tolerability of Gabapentin 500mg in a Potential OTC Population

2005 Investigator; Neurocrine Biosciences, Inc.; Phase III, Randomized, Double-Blind, Placebo-Controlled, Polysomnographic Study to Assess the Efficacy and Safety of a modified Release Formulation of NBI-34060 in Primary Insomnia Patients with Sleep Maintenance Difficulties

2006 Eli Lilly & Co.; A Comparison of CS-747 and Clopidrogel in Acute Coronary Syndrome Subjects who are to undergo Percutaneous Coronary Intervention/TIMI-38

2007 Investigator: Sanofi-Aventis; A gLycemic control Evaluation of Glimerpiride versus Rimonabant on tOp of metformin in type 2 diabetes/ALLEGRO study.

2012 Sub-Investigator; The Effect of Dulaglutide on Major Cardiovascular Events in Patients with Type 2 Diabetes: Researching Cardiovascular Events with a Weekly INcretin in Diabetes (REWIND)

2012 A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of SAR236553/REGN727 in High Cardiovascular Risk Patients With Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy (ODYSSEY COMBO 1)

2015 Alder Biopharmaceuticals ALD403-CLIN-005 A Parallel Group, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging Phase 2 Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of ALD403 Administered Intravenously in Patients with Chronic Migraine

2015 Daiichi Sankyo DS5565-A-E311A Randomized, Double-Blind, Placebo- and Active-Controlled Study of DS-5565 in Subjects with Pain Associated with Fibromyalgia

2015 Daiichi Sankyo DS5565-A-E312 An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated with Fibromyalgia

1VIT14037: A Double-Blinded, Multi-Center, Randomized, Placebo-Controlled Study to Investigate the Efficacy and Safety of Injectafer® (Ferric Carboxymaltose) in the Treatment of Restless Legs Syndrome (RLS)

1002-048: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of Bempedoic Acid (ETC-1002) 180 mg/day as Add-on to Ezetimibe Therapy in Patients with Elevated LDL-C

Protocol: JZP080-301 A Double-blind, Placebo-controlled, Randomized Withdrawal, Multicenter Study of the Efficacy and Safety of JZP-258 in the Treatment of Idiopathic Hypersomnia (IH) with an Open-label Safety Extension

A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Immunogenicity, Safety, Reactogenicity, and Consistency of a Heterologous2-dose Vaccine Regimen Using 3 Consecutive Lots of Ad26, ZEBOV and MVA-BN-Filo in Adult Participants